---
title: "Novartis India Ltd (NOVARTIND) — Share Price, Financials & Analysis"
symbol: "NOVARTIND"
company: "Novartis India Ltd"
canonical: "https://tapetide.com/stocks/NOVARTIND"
isin: "INE234A01025"
nse_symbol: "NOVARTIND"
bse_code: "500672"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 5772.96
generated_at: "2026-09-13T19:15:28.298Z"
---

# Novartis India Ltd (NOVARTIND)

Canonical page: https://tapetide.com/stocks/NOVARTIND

## Company

- **NSE Symbol:** NOVARTIND
- **BSE Code:** 500672
- **ISIN:** INE234A01025
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2026-04-20
- **CEO:** Ms. Shilpa Shashank Joshi
- **Employees:** 56
- **Face Value:** ₹5
- **F&O Eligible:** No
- **Website:** novartis.in

## About

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.
[1] It imports various medicines to India from different sources across the globe.[2]

## Latest Price

- **Price:** ₹2391.3
- **Change:** -36.9 (-1.52%)
- **Open:** ₹2380
- **Day High:** ₹2550
- **Day Low:** ₹2262.1
- **Previous Close:** ₹2428.2
- **Volume:** 454582
- **As Of:** 2026-09-11T10:29:09+00:00

## Key Fundamentals

Observed at 2026-09-11T04:50:38.724590Z.

- **Market Cap:** ₹5772.96 Cr
- **Classification:** Microcap
- **P/E (reported):** 61.2
- **P/E (TTM):** 60.37
- **EPS (TTM):** ₹39.61
- **Book Value:** ₹331.23
- **Price to Book:** 7.32
- **Dividend Yield:** 1.03%
- **ROE:** 11.39%
- **ROCE:** 15.71%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹393.1 Cr
- **Net Income:** ₹93.2 Cr
- **EBITDA:** ₹132.9 Cr
- **52-Week High:** ₹2588.8
- **52-Week Low:** ₹950
- **RSI (14):** 88.47

## Tapetide Score

- **Score:** 59 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 84.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 91.18 | 9% |
| growth | 21.4 | 9% |
| momentum | 98.9 | 12% |
| ownership | 49.58 | 24% |
| quality | 58.8 | 22% |
| valuation | 48.06 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 66.6%

### Weaknesses

- Stock is trading at 7.22 times its book value
- The company has delivered a poor sales growth of -1.46% over past five years.
- Company has a low return on equity of 11.9% over last 3 years.
- Earnings include an other income of Rs.36.9 Cr.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -37.33% | -58.79% | 20.84% |
| ebitda margin growth | 42.81% | 0.93% | 5.66% | 142.82% |
| net income growth | 27.27% | -7.63% | -3% | 35% |
| revenue growth | 11.93% | -1.28% | -2% | -1% |
| roce | — | -3.5% | -2.96% | 12.51% |
| roe | — | -11.36% | 11.89% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 |
| Expenses | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 |
| Operating Profit | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 |
| OPM % | 21 | 23 | 14 | 26 | 21 | 28 | 29 | 31 | 26 | 26 | 23 | 34 |
| Other Income | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Profit before tax | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 |
| Tax % | 27 | 36 | 31 | 24 | 26 | 28 | 14 | 26 | 26 | 46 | 16 | 25 |
| Net Profit | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 |
| EPS in Rs | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 356 | 354 | 371 |
| Expenses | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 265 | 260 | 269 |
| Operating Profit | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 91 | 94 | 102 |
| OPM % | -1.1 | 2.5 | 2.8 | 7 | 7 | 17 | 19 | 26 | 27 | 27 |
| Other Income | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | 39 | 37 |
| Interest | 6 | 2 | 6 | 8 | 5 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 13 | 12 | 10 | 6 | 3 | 2 | 2 | 2 |
| Profit before tax | 158 | 86 | 29 | 40 | -4 | 115 | 123 | 130 | 130 | 136 |
| Tax % | 50 | 40 | 65 | 48 | -3 | 10 | 31 | 23 | 28 | — |
| Net Profit | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 101 | 93 | 98 |
| EPS in Rs | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.5 | 40.87 | 37.74 | 39.61 |
| Dividend Payout % | 32 | 48 | 245 | 118 | -663 | 113 | 72 | 61 | 66 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 | 805 |
| Borrowings | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 5 | 3 |
| Other Liabilities | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | 157 |
| Total Liabilities | 1150 | 1111 | 982 | 1078 | 1002 | 958 | 983 | 925 | 948 | 978 |
| Fixed Assets | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1144 | 1106 | 967 | 1001 | 938 | 934 | 964 | 918 | 943 | 975 |
| Total Assets | 1150 | 1111 | 982 | 1078 | 1002 | 958 | 983 | 925 | 948 | 978 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | 75 | 47 |
| Cash from Investing Activity | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | 18 |
| Cash from Financing Activity | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | -64 |
| Net Cash Flow | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 | 0 |
| Free Cash Flow | -44 | 160 | -208 | -24 | -69 | 38 | 45 | 113 | 75 | 46 |
| CFO/OP | 13 | -3503 | -1210 | 124 | -127 | 210 | 65 | 115 | 99 | 87 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 | 38 |
| Inventory Days | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 | 74 | 98 |
| Days Payable | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 | 93 | 101 |
| Cash Conversion Cycle | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 | 22 | 36 |
| Working Capital Days | -14 | -99 | 7 | -1 | 62 | -23 | -37 | -59 | -45 | -46 |
| ROCE % | 9 | 17 | 12 | 5 | 6 | 6 | 15 | 16 | 17 | 16 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FIIs | 0.32% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.17% | 0.16% |
| DIIs | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.53% | 0.64% | 0.53% | 1.36% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 23.29% | 23.21% | 22.95% | 23.04% | 23.05% | 23.01% | 23.11% | 22.95% | 22.92% | 22.67% | 23.25% | 22.5% |
| Others | 5.18% | 5.39% | 5.65% | 5.57% | 5.55% | 5.59% | 5.49% | 5.66% | 5.68% | 5.83% | 5.36% | 5.31% |
| No. of Shareholders | 43992 | 43128 | 41239 | 39265 | 39596 | 38926 | 39133 | 39040 | 39353 | 39468 | 38116 | 36502 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 2 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1846.63 | Buy |
| EMA (10) | 1953.25 | Buy |
| SMA (20) | 1676.99 | Buy |
| EMA (20) | 1786.59 | Buy |
| SMA (50) | 1623.87 | Buy |
| EMA (50) | 1623.42 | Buy |
| SMA (100) | 1453.82 | Buy |
| EMA (100) | 1411.39 | Buy |
| SMA (200) | 881.9 | Buy |
| EMA (200) | 1117.73 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 85.23 | Sell |
| MACD (12,26,9) | 164.7 | Buy |
| Stochastic (14,3,3) | 89.6 | Sell |
| ADX (14) | 35.23 | Buy |
| Williams %R (14) | -17.52 | Sell |
| ATR (14) | 132.41 | High Volatility |
| ROC (12) | 60.48 | Buy |
| Stoch RSI (14) | 92.84 | Sell |
| UO (7,14,28) | 67.51 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Apr - Novartis AG reiterates sale of 70.68% stake to WaveRise, ChrysCapital and Two Infinity Partners under February 19 SPA. | [Disclosure Under Regulation 31(4) Of The SEBI (Substantial Acquisition Of Shares And Takeover Regulations, 2011) 7 Apr - Novartis AG reiterates sale of 70.68% stake to WaveRise, ChrysCapital and Two Infinity Partners under February 19 SPA.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1211dd9a-d524-4cc8-8ac3-707d34ad8293.pdf) |
| 6 Mar - Novartis received Draft Letter of Offer dated March 05, 2026 for open offer by ChrysCapital, WaveRise, Two Infinity. | [Intimation Of Receipt Of Draft Letter Of Offer Received From Manager To Open Offer (Axis Capital Limited). 6 Mar - Novartis received Draft Letter of Offer dated March 05, 2026 for open offer by ChrysCapital, WaveRise, Two Infinity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0b32c70a-23b1-4e39-aec5-a39336a141f5.pdf) |
| 6 Mar - Acquirers offer to buy 64,19,608 Novartis India shares (26%) at INR 860.64, Tendering Period Apr21–May5, 2026. | [Draft Letter of Offer 6 Mar - Acquirers offer to buy 64,19,608 Novartis India shares (26%) at INR 860.64, Tendering Period Apr21–May5, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7EBA61B6-FCFE-4949-99C6-676042C689F1-120454.pdf) |
| 31 Mar - Board meeting May 12, 2026 to approve audited results for year ended Mar 31, 2026; trading window closed Apr 1. --- Checklist: - Identify regulatory … | [Board Meeting Intimation for Intimation Of Meeting Of The Board Of Novartis India Limited ('The Company') And Closure Of Trading Window. 31 Mar - Board meeting May 12, 2026 to approve audited results for year ended Mar 31, 2026; trading window closed Apr 1. --- Checklist: - Identify regulatory …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b72ccaac-bfc9-42e4-9845-6c8e288a1e38.pdf) |
| 30 Mar - Delhi High Court admitted petition challenging DVAT demand ~INR10.89 crore and penalty ~INR6.85 crore (petition received March 29, 2026) | [Intimation Of The Receipt Of Delhi High Court Order Admitting Company Petition In The Matter Of Novartis India Limited Vs. Commissioner Of Trade And Taxes (W.P.(C) 3892/2026) 30 Mar - Delhi High Court admitted petition challenging DVAT demand ~INR10.89 crore and penalty ~INR6.85 crore (petition received March 29, 2026)](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aa1a2cf5-5af0-4144-89ed-76717b5b27f7.pdf) |
| 27 Mar - Notice (26 Mar) and order (27 Mar 2026) for INR 10.28 crore TDS demand; appeal and stay planned. | [Intimation Under Reg 30 Of SEBI LODR Of Receipt Of TDS Order As Per Income Tax Act 27 Mar - Notice (26 Mar) and order (27 Mar 2026) for INR 10.28 crore TDS demand; appeal and stay planned.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7992401f-fcca-4d69-ab4c-48b1aa21e66d.pdf) |
| 27 Mar - Appoint Gowree Gokhale as Independent Director from April 1, 2026 (5-year term); Sandra Martyres exits April 18, 2026; postal ballot. | [Announcement under Regulation 30 (LODR)-Change in Management 27 Mar - Appoint Gowree Gokhale as Independent Director from April 1, 2026 (5-year term); Sandra Martyres exits April 18, 2026; postal ballot.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bad8da26-b3a1-41ae-9b18-a1c616223a32.pdf) |
| 26 Feb - Open offer at INR 860.64 for 26% (64.19 lakh) shares; SPA sells 70.68% to Acquirers. | [Announcement under Regulation 30 (LODR)-Public Announcement-Open Offer 26 Feb - Open offer at INR 860.64 for 26% (64.19 lakh) shares; SPA sells 70.68% to Acquirers.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f34c8fe-9c9f-41bd-82f2-ea43e3113ee9.pdf) |
| 26 Feb - Mandatory open offer for 26% of Novartis India at INR860.64; SPA transfers 70.68% control to Acquirers. | [Detailed Public Statement 26 Feb - Mandatory open offer for 26% of Novartis India at INR860.64; SPA transfers 70.68% control to Acquirers.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/E4F66B93-DA75-4FB6-9BFE-781416D9CE02-181410.pdf) |
| 23 Apr - Novartis India says it is not a Large Corporate; outstanding borrowings were nil as of March 31, 2025. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 23 Apr - Novartis India says it is not a Large Corporate; outstanding borrowings were nil as of March 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/544a8125-77a9-4321-b953-7da45cbe8d58.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Intimation Pursuant To Regulation 36(1)(B) Of SEBI LODR Regulations](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98175f40-2d1c-4746-a5fc-b4a71c715238.pdf) |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e10c201-1478-40a1-8dd0-fc6eaa8ed2bf.pdf) |
| 2026-09-08 | [Intimation Under Reg 30 Of SEBI LODR Regarding Entering Into Exclusive Promotion And Distribution Agreement With Novartis Healthcare Private Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f76e211a-677f-46ec-a2b0-d716daf6bd74.pdf) |
| 2026-09-07 | [Intimation Regarding The Acquisition Of Trademarks "Minipress" And "Minipres" From Pfizer Inc. USA And Pfizer Products Inc. USA The Same Is Approved By The Board Of Directors Of The Company At Their Board Meeting Held Today I.E. September 07 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bfefbf7-f0ff-45a9-a9e3-91ef8ee696c2.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e8a58a2-e06f-4af8-bbae-1d778320ff74.pdf) |
| 2026-09-02 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a8d48d01-6c2d-4cc7-9e8b-bc5ef0b319c3.pdf) |
| 2026-09-02 | [Notice Of The 78Th Annual General Meeting Of Novartis India Limited To Be Held On Thursday September 24 2026 Through Video Conferencing (VC) / Other Audio Visual Means (OAVM)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f93f314-4519-4ef6-be0a-b2a0a9e3ac1b.pdf) |
| 2026-09-02 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ae7a09e-cbe6-4842-8196-329748e70ea3.pdf) |
| 2026-08-28 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=67d1c69f-904e-48e1-ad20-a9d962dd2ecb.pdf) |
| 2026-08-17 | [Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company Held On August 17 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf3e860d-5623-463b-8381-455991e3464e.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-23 | [Financial Results Of Novartis India Limited For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=155fb5bd-acc7-4f62-b613-9ab3e5ae241e.pdf) |
| 2026-05-12 | [Integrated Financial Results For The Quarter And Financial Year Ended March 31 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e743d4b-904a-4fc8-80c8-881e9e32a863.pdf) |
| 2026-01-28 | [Integrated Filing (Financial) For The Quarter Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bcbcb00e-9aa6-4e62-a609-aa0914ade777.pdf) |
| 2025-10-28 | [Integrated Unaudited Financial Results And Limited Review Report For The Quarter And Half-Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06eda567-07be-42ce-920f-f90cabaad4a7.pdf) |
| 2025-07-29 | [Unaudited Financial Results For The Quarter Ended As On June 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2b0c7bfd-e2c1-4755-8663-2d2e83f5a238.pdf) |
| 2025-05-09 | [Financial Results For The Quarter And Year Ended As On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3d25b0d-74c4-4a61-93f7-3d1935195d3a.pdf) |
| 2025-01-28 | [Filing Of Unaudited Financial Results And Limited Review Report For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6bab3dbe-22fa-4099-a83f-1cb2f8e76996.pdf) |
| 2024-10-25 | [Filing Of The Outcome Of Board Meeting And Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6577711-ef26-4348-b849-5d845d909221.pdf) |
| 2024-07-29 | [Outcome - Unaudited Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=179c1dd7-8cb6-432f-8f21-5337569dbcbd.pdf) |
| 2024-07-29 | [Results - Unaudited Financial Results For The First Quarter Ended June 30, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d07197a8-a5e5-49b0-8b7b-9b100741c5f0.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4ca2b229-36f0-4585-9c8e-5e0d077304c4.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b0205b9-16fe-4d7a-804f-d67959700767.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b415137f-f341-406c-ad13-6aa820190ca1.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/73362500672.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/69195500672.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720320.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/500672/5006720316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:15:28.298Z.